Compare Novo Nordisk A/S (NVO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tencent Music Entertainment Group - ADR — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while Tencent Music Entertainment Group - ADR trades at $7.96 (market cap $13.50B). The key difference: Novo Nordisk A/S is far larger — about 14.9× Tencent Music Entertainment Group - ADR's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | TME | |
|---|---|---|
Market Cap | $200.69B | $13.50B |
Sector | Health | Media |
52-Week High | $63.98 | $26.36 |
52-Week Low | $35.29 | $7.89 |
Enterprise Value | $215.49B | $11.44B |
Dividend Yield | 3.98% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with a bearish technical signal from moving averages but oversold RSI levels. The company reported strong Q2 2026 earnings with a beat on EPS and revenue growth of 6% year-over-year, though recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
The outlook is balanced: TME's low P/E of 9.46 and net income margin of 26.28% offer value, but slowing growth and rising debt pose risks. Analysts have a consensus price target of $12.15, suggesting upside, but investors should weigh competitive threats from rivals like ByteDance's Soda Music against the company's fan economy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
